Blood–Brain Barrier Driven Pharmacoresistance in Amyotrophic Lateral Sclerosis and Challenges for Effective Drug Therapies

@article{Mohamed2017BloodBrainBD,
  title={Blood–Brain Barrier Driven Pharmacoresistance in Amyotrophic Lateral Sclerosis and Challenges for Effective Drug Therapies},
  author={Loqman A. Mohamed and Shashirekha S. Markandaiah and Silvia Bonanno and Piera Pasinelli and Davide Trotti},
  journal={The AAPS Journal},
  year={2017},
  volume={19},
  pages={1600-1614}
}
The blood–brain barrier (BBB) is essential for proper neuronal function, homeostasis, and protection of the central nervous system (CNS) microenvironment from blood-borne pathogens and neurotoxins. The BBB is also an impediment for CNS penetration of drugs. In some neurologic conditions, such as epilepsy and brain tumors, overexpression of P-glycoprotein, an efflux transporter whose physiological function is to expel catabolites and xenobiotics from the CNS into the blood stream, has been… CONTINUE READING
7
Twitter Mentions

Figures, Tables, and Topics from this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 162 REFERENCES

Transporters as Drug Targets in Neurological Diseases.

  • Clinical pharmacology and therapeutics
  • 2016
VIEW 4 EXCERPTS

Expression and function of multidrug resistance transporters at the blood-brain barriers.

  • Expert opinion on drug metabolism & toxicology
  • 2005
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Characterisation of the brain multidrug resistance protein (BMDP/ABCG2/BCRP) expressed at the blood-brain barrier

T Eisenblatter, S Huwel, HJ. Galla
  • Brain Res
  • 2003
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

P-glycoprotein Inhibition for Optimal Drug Delivery

  • Drug target insights
  • 2013
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL